Our goal is to provide the necessary tools for doctors and medical staff to make optimal treatment decisions that can ultimately improve public health as a whole. We believe our technology and processes can replace or augment current diagnostic paradigms in a range of settings, such as hospitals, independent diagnostic testing facilities, veterinary and livestock clinics, and research institutions.
PathoGene’s patented, fully-automated, sample-to-answer IVD medical device will detect and identify all infectious bacterial, viral, fungal, and parasitic pathogens and profile antimicrobial resistance in clinical samples.
Significantly faster and more accurate diagnostic testing improves patient outcomes by reducing hospital length of stay & healthcare costs, lowering risks of long-term complications, and reducing patient mortality.
Fully-automated workflows enable untrained laboratory personnel to operate cutting-edge nanopore sequencing technology at a cost comparable to microbiological culture with sensitivity testing.
PathoGene's best-in-class diagnostic testing platform will ensure the United States remains prepared for any biosecurity threat, like SARS-COV-2, Monkeypox, filoviruses, anthrax, and other Category A bioterrorism agents.
Cost-effective diagnostic solutions for livestock and pets will improve business operations and animal well-being across the board while reducing unnecessary antimicrobial drug use and agricultural waste.